Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M800Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M8.9EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)20.0Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book1.810-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %3.7PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M52,150,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with PID

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

PID is held by these investors:

PID: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Rapps, MichaelDirector, Director or Senior Officer of 10% Securi 2017-01-16Buy1,200$9.4862.13view
Gridley, Anthony RonaldSenior Officer 2017-01-16Sell1,800$16.94-9.27view
Dinwoodie, Tyler Wayne PaulSenior Officer 2017-01-16Buy4,000$0.178941.18view
Brown, Mark ThomasDirector 2017-01-16Sell29,300$1.361030.15view
Bebek, IvanDirector 2017-01-16Buy8,990$3.38354.73view
smith, laurie james10% Security Holder, Director, Senior Officer 2017-01-16Buy7,500$0.413648.78view
MEHR, JEFFREYSenior Officer 2017-01-13Sell50,000$27.91-44.93view
Squibb, Geoffrey WayneDirector 2017-01-13Buy267$6.27145.14view
Smith, DavidSenior Officer 2017-01-13Sell15,000$60.38-74.54view
Rowlands, William BruceDirector, Senior Officer 2017-01-13Buy20,000$0.1510146.67view

Quarterly/Annual Reports about PID:

    News about PID:

    Articles On GuruFocus.com
    Searching The World For The Best Dividend Stocks Jan 06 2015 

    More From Other Websites
    Don't Sell, Buy 4 High Dividend ETFs Under $20 in May May 02 2017
    How GlaxoSmithKline’s Vaccines Business Performed in 1Q17 May 02 2017
    How GlaxoSmithKline’s Business Segments Performed in 1Q17 May 01 2017
    Novartis’s 1Q17 Earnings: Innovative Medicines Segment Apr 27 2017
    GlaxoSmithKline’s 1Q17 Estimates: Vaccines Business Apr 26 2017
    Analyst Ratings and Recommendations for Novartis Apr 24 2017
    Analyst Estimates for Novartis’s 1Q17 Earnings Apr 21 2017
    Novartis Expects to Restore Alcon’s Profitability in the Future Apr 04 2017
    Sanofi Genzyme Continued Growth in 2016 Apr 03 2017
    Reduced Co-pays May Boost Demand for Entresto Mar 30 2017
    Performance of GlaxoSmithKline’s Vaccines Business in 2016 Mar 30 2017
    GlaxoSmithKline’s Pharmaceuticals Segment Performance Mar 29 2017
    With low yields abroad, investors hunt for international dividend funds Mar 28 2017
    Sandoz: Novartis’s Generics Business in 2016 Mar 27 2017
    Novartis’s Innovative Medicines Segment in 2016 Mar 27 2017
    What Happened to Sanofi’s Valuation after 4Q16? Feb 21 2017
    GlaxoSmithKline’s Consumer Healthcare Reports Growth in 4Q16 Feb 16 2017
    GlaxoSmithKline’s Vaccines Business Reported Growth in 4Q16 Feb 15 2017
    4Q16 Performance of GlaxoSmithKline’s Business Segments Feb 14 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)